REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing targeted therapies for patients with RASaddicted cancers, today announced its financial results for the quarter ended June 30, 2024, and provided an update on corporate progress. The company continues making progress on its 2024 development priorities: Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials. Pancreatic cancer: The com ...

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter an ...

REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter 2024 on Wednesday, August 7, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter an ...

Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) REDWOOD CITY, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publ ...

The sudden soaring of the stock price can be attributed to the positive investor mindset regarding the progress in the development of Revolution's lead investigational candidate, RMC-6236. The company is currently evaluating RMC-6236 as a monotherapy as well as in combination with other agents in seprate early-stage studies across a variety of oncology indications. Revolution's clinical-stage pipeline also comprises two other early-stage candidates, being devolped for solid tumour indications. Earnings and ...

REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide an update on its RMC-6236 pancreatic ductal adenocarcinoma (PDAC) clinical development program. Speakers will include members of Revolution Medicines' management team, along with Brian M. Wolpin, M.D., M.P.H., professor of medicine at Harvard M ...

The webcast will take place at 8:00 a.m. Eastern Time on Monday, July 15, 2024. To access the live webcast, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the "Events & Presentations" page of the Revolution Medicines website for at least 14 days following the event. About Revolution Medicines, Inc. REDWOOD CITY, Calif., July 08, 2024 (GLOBE NEWSWIRE) -- Revolution Me ...

NEW YORK, July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Revolution Medicines, Inc. (NASDAQ: RVMD) on behalf of the company's shareholders. The investigation seeks to determine whether Revolution Medicines's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Revolution Medicines, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us ...

Financial Data and Key Metrics Changes - The company ended Q1 2024 with $1.7 billion in cash and investments, down from $1.85 billion at the end of 2023, primarily due to net loss and a decrease in accounts payable and accrued liabilities [15][34] - R&D expenses for Q1 2024 were $118.0 million, compared to $68.9 million in Q1 2023, driven by clinical trial expenses [34] - The net loss for Q1 2024 was $116.0 million, or $0.70 per share, with a projected full-year GAAP net loss expected to be between $480 million and $520 million [35] Business Line Data and Key Metrics Changes - The company is focused on advancing RMC-6236 into pivotal monotherapy trials for major cancers driven by oncogenic RAS variants, with updates expected in the second half of the year [23][24] - RMC-6236 is being evaluated in combination studies for pancreatic and colorectal cancers, which are crucial for establishing first-line registrational paths [9][10] Market Data and Key Metrics Changes - The company anticipates that the first registrational studies for RMC-6236 will launch in the second half of the year, targeting advanced pancreatic cancer and non-small cell lung cancer [14][24] - The competitive landscape includes other KRAS G12C inhibitors, but the company believes that RMC-6236 will provide a treatment option for patients without G12C mutations [42][44] Company Strategy and Development Direction - The company has outlined three strategic priorities for 2024: advancing RMC-6236 into pivotal trials, expanding its reach beyond G12X mutations, and qualifying its first two RAS(ON) mutant-selective inhibitors [4][25][28] - The company is exploring combination therapies to enhance treatment efficacy and is committed to moving RMC-6236 into earlier lines of therapy [27][29] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of RMC-6236, citing complete responses in some patients and the importance of targeting RAS addiction [26][32] - The company is well-capitalized and focused on delivering key data to advance its clinical programs, with a strong emphasis on safety and efficacy in combination therapies [36][37] Other Important Information - The company presented data at the AACR Annual Meeting, highlighting the potential of RMC-6236 across various RAS genotypes and tumor types [25][80] - Management emphasized the importance of establishing safety profiles for combination therapies before moving forward with clinical development [106][107] Q&A Session Summary Question: What questions are still being addressed for the pancreatic cancer study design? - The company needs to reach an agreement with the FDA on dosing and trial design, which are expected to be resolved in the first half of the year [37] Question: Will the first-line study wait for second-line trial results? - The company is evaluating both monotherapy and combination options for first-line treatment but has not made a definitive decision yet [39] Question: How might the KRYSTAL 12 trial results impact the company's studies? - The company believes that the impact will be minimal for pancreatic cancer, as G12C represents a small subpopulation [42] Question: What is the expected timeline for initial data from the RMC-6236 and pembrolizumab combination? - Initial safety data will likely not be from first-line patients, but the study is designed to enable a first-line strategy [46][51] Question: What is the company's approach to business development? - The company is committed to U.S. operations and plans to commercialize its compounds independently, while seeking partners for international markets [117][124]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-2029180 | | --- | ...